SOW
CRVS icon

State of Wyoming’s Corvus Pharmaceuticals CRVS Stock Holding History

State of Wyoming’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.7K Buy
+4,735
New +$65.7K 0.01% 1577

Other funds holding CRVS

EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
TL
TowerView LLC New York $152M AUM 20.28% 1-Year Est. Return

State of Wyoming's CRVS Position: Q2 2026 in Review

State of Wyoming opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 4,735 shares worth $70.7K. The stake represents 0.01% of the portfolio and ranks #1577 among its holdings.

42 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • State of Wyoming held 4,735 shares of Corvus Pharmaceuticals worth $70.7K as of Q2 2026.
  • Corvus Pharmaceuticals was a new State of Wyoming position in Q2 2026.
  • Corvus Pharmaceuticals made up 0.01% of State of Wyoming's portfolio in Q2 2026, its #1577 holding.
  • 42 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.